Novartis Pharmaceuticals Corp. v. Handa Pharmaceuticals, Inc.
Unverified- Docket:
- 1:22-cv-00352
- Filed:
- 2022-03-21
Patents:9187405
Suit against Handa Pharmaceuticals asserting the '405 patent; details and outcome not verified from the narrative.
Plaintiff
Novartis Pharmaceuticals Corp.
8 cases as plaintiff.
- Cases
- 8
- Active
- 1
- 7 closed
- Filed
- 2018–2022
- Top venue
- D. Delaware
- 6 cases
Watchlist
Get alerted when Novartis Pharmaceuticals Corp. sues again.
Email-only, free, anonymous. We'll notify you when Novartis Pharmaceuticals Corp. files another patent-infringement lawsuit. One-click unsubscribe from any alert.
Novartis Pharmaceuticals Corp. v. Apotex Inc.
Settled- Docket:
- 1:18-cv-01038
- Filed:
- 2018-07-13
Patents:9187405
ANDA/Hatch-Waxman suit against Apotex asserting the '405 patent; resolved by confidential settlement licensing entry before patent expiry.
Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc. et al.
Reversed on rehearing; claims invalid- Docket:
- 21-1070
Patents:9187405
Appeal from D. Del. 1:18-cv-01043. The Federal Circuit first affirmed validity and infringement on January 3, 2022, then on rehearing vacated and reversed, holding the '405 patent claims invalid for lack of written description (38 F.4th 1013). Rehearing en banc was denied and mandate issued approximately October 18, 2022.
Novartis Pharmaceuticals Corp. v. HEC Pharm Co., Ltd.
Certiorari denied- Docket:
- 22-671
Patents:9187405
Petition for certiorari from the Federal Circuit's invalidation of the '405 patent; emergency stay of mandate was granted by Chief Justice Roberts on 2022-09-29; certiorari was denied (143 S. Ct. 1748).
Novartis Pharmaceuticals Corp. v. Teva Pharmaceuticals USA, Inc.
Settled- Docket:
- 1:18-cv-01039
Patents:9187405
ANDA suit against Teva (ANDA No. 208008) asserting the '405 patent; filed around 2018-07-16 and settled.
Novartis Pharmaceuticals Corp. v. Sun Pharma Global FZE et al.
Settled- Docket:
- 1:18-cv-01040
Patents:9187405
ANDA suit against Sun Pharma entities asserting the '405 patent; filed around 2018-07-16 and settled.
Novartis Pharmaceuticals Corp. v. Mylan Pharmaceuticals Inc.
Settled; consent judgment/injunction- Docket:
- 1:19-cv-01118-LPS
Patents:9187405
ANDA suit against Mylan (ANDA No. 208005) asserting the '405 patent; settled with proposed consent judgment and injunction filed 2020-10-26; later dispute over post-CAFC launch led to TRO entered 2022-10-11.
Novartis Pharmaceuticals Corp. v. Handa Neuroscience, LLC et al.
Discovery active through mid-2022; final disposition unverified- Docket:
- 1:21-cv-00645
π Novartis Pharmaceuticals Corp.Δ Handa Neuroscience, LLCΔ Handa Pharma, Inc.Δ Handa Pharmaceuticals, Inc.Δ Handa Pharmaceuticals, LLC
Suit against Handa entities asserting the '405 patent and also US 10,543,179. Handa sought summary judgment on the '405 patent after the Federal Circuit's June 2022 invalidation; final disposition not verified.